[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654454":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":25,"interventions":40,"overallOfficials":11,"centralContacts":54,"locations":60,"responsibleParty":86,"collaborators":11,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":111,"whyStopped":11,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Eddingpharm (Zhuhai) Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Percentage Change from Baseline in Serum Triglycerides (TG) Levels at Week 24",null,"From baseline to week 24 of the core study",[14],{"measure":15,"description":11,"timeFrame":12},"Percentage and absolute change of TG, LDL-C, non-HDL-C, TC, VLDL-C, HDL-C, ApoB and ANGPTL3 from baseline to Week 24 (excluding the primary endpoint)",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":22},"DOUBLE",[23,24],"PARTICIPANT","INVESTIGATOR",[26,31,36],{"label":27,"type":28,"description":11,"interventionNames":29},"Cohort 1 EDP167 100 mg or volume-matched placebo","EXPERIMENTAL",[30],"Drug: EDP167 100mg",{"label":32,"type":33,"description":11,"interventionNames":34},"Cohort 2 EDP167 200 mg or volume-matched placebo","ACTIVE_COMPARATOR",[35],"Drug: EDP167 200mg",{"label":37,"type":33,"description":11,"interventionNames":38},"Cohort 3 EDP167 300mg or volume-matched placebo",[39],"Drug: EDP167 300mg",[41,46,50],{"type":42,"name":43,"description":44,"armGroupLabels":45,"otherNames":11},"DRUG","EDP167 100mg","EDP167 100 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 100 mg once every 3 months in the extension study.",[27],{"type":42,"name":47,"description":48,"armGroupLabels":49,"otherNames":11},"EDP167 200mg","EDP167 200 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 200 mg once every 3 months in the extension study.",[32],{"type":42,"name":51,"description":52,"armGroupLabels":53,"otherNames":11},"EDP167 300mg","EDP167 300 mg or volume-matched placebo sc once every 12 weeks in the core study, and EDP167 300 mg once every 3 months in the extension study.",[37],[55],{"name":56,"role":57,"phone":58,"phoneExt":11,"email":59},"WEI Song","CONTACT","86-13817957624","Sophie.Song@eddingpharm.com",[61,75],{"facility":62,"status":11,"city":63,"state":11,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":72},"The 2nd Affiliated Hospital of Harbin Medical University","Harbin","China","CN",{"type":67,"coordinates":68},"Point",[69,70],126.65,45.75,{"lat":70,"lon":69},[73],{"name":74,"role":57,"phone":11,"phoneExt":11,"email":11},"Bo Yu",{"facility":76,"status":11,"city":77,"state":11,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"The Second Affiliated Hospital Zhejiang University School of Medicine","Zhejiang",{"type":67,"coordinates":79},[80,81],105.583,25.3238,{"lat":81,"lon":80},[84],{"name":85,"role":57,"phone":11,"phoneExt":11,"email":11},"Jian'an Wang",{"type":87,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654454","phase-2-phase-2-dose-finding-study-evaluating-the-efficacy-and-safety-of-edp167-in-adults-with-mixed-dyslipidemia-100654454",false,"NCT07799129","Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Study to Evaluate the Efficacy and Safety of EDP167 in Adult Patients With Mixed Dyslipidemia","Inclusion Criteria:\n\n* Participants aged ≥18 years and ≤75 years at the time of signing the informed consent form, male or female, with a BMI of ≥18.5 and \\\u003C40 kg\u002Fm²;\n* Fasting serum TG at screening: TG ≥ 150 mg\u002FdL (1.7 mmol\u002FL) and \\\u003C 500 mg\u002FdL (5.6 mmol\u002FL), and LDL-C ≥ 70 mg\u002FdL (1.8 mmol\u002FL)\n* Willing to maintain a routine low-fat diet throughout the study\n* Have received stable-dose statin therapy of moderate intensity or higher for at least 4 weeks prior to lipid testing at screening (unless statin-intolerant).\n\nExclusion Criteria:\n\n* Participants who have used any antisense oligonucleotide (ASO) or small interfering RNA (siRNA) agents within 12 months prior to randomization;\n* Participants who have received or are receiving ANGPTL3- or ApoC3-targeted therapy, or have participated in any other clinical drug study within 6 months prior to screening or within 5 half-lives (whichever is longer);\n* Participants planning to undergo bariatric surgery or weight-loss intervention during the study;\n* Participants with uncontrolled medical conditions that may affect lipid or lipoprotein levels, such as nephrotic syndrome, severe hepatic disease, Cushing's syndrome, thyroid disorders, etc.;\n* Participants with a history of acute pancreatitis within 12 weeks prior to randomization;\n* Participants with a history of acute coronary syndrome, stroke, or NYHA Class III-IV heart failure within 24 weeks prior to randomization;\n* Participants who have undergone coronary intervention within 24 weeks prior to randomization or plan to receive coronary intervention or pacemaker implantation during the study;\n* Participants with a history of major surgery within 12 weeks prior to screening or scheduled elective surgery requiring hospitalization during the study;\n* Participants with uncontrolled hypertension at screening.","ALL","18 Years","75 Years",{"count":99,"type":100},144,"ESTIMATED","INTERVENTIONAL",[103],"PHASE2","EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting angiopoietin-like 3 protein (ANGPTL3), which may bring benefits for patients with dyslipidemia conditions. This Phase 2 clinical study comprises two phases: a randomized, double-blind, placebo parallel-controlled core study and an open-label extension study.",[106],"Mixed Dyslipidemia",[108,109,110,106],"Dyslipidemia","ANGPTL3","siRNA","NOT_YET_RECRUITING","2026-08-31",{"date":114,"type":115},"2026-09-02","ACTUAL",{"date":117,"type":100},"2026-11",{"date":119,"type":100},"2028-04",{"name":5,"class":6},2]